- Home
- AYTU vs ACCS Comparison
AYTU vs ACCS Comparison
Compare AYTU & ACCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AYTU | ACCS |
|---|---|---|
| Founded | N/A | 1988 |
| Country | United States | United States |
| Employees | N/A | 91 |
| Industry | Biotechnology: Pharmaceutical Preparations | Publishing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 25.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AYTU | ACCS |
|---|---|---|
| Price | $2.18 | $6.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $9.33 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 20.7K | 7.1K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,632,080.00 | N/A |
| Revenue This Year | N/A | $7.40 |
| Revenue Next Year | $43.75 | $8.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.47 | N/A |
| 52 Week Low | $1.65 | $5.80 |
| 52 Week High | $3.07 | $13.10 |
Technical Indicators
Market Signals| Indicator | AYTU | ACCS |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | N/A |
| Support Level | $2.10 | N/A |
| Resistance Level | $2.31 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 30.77 | 0.00 |
Price Performance
Historical ComparisonAbout AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
About ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.